New pill could ease rare bone disease
NCT ID NCT07179640
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This early-stage trial tests an oral drug called ALE1 for hypophosphatasia (HPP), a rare genetic bone disease. The study will first check safety and how the drug moves through the body in healthy volunteers, then in adult HPP patients. It is a small, placebo-controlled study to find the right dose and see if the drug is safe enough to test further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALE1 (an oral drug)
- What this could lead to
- If successful, this could point toward a new oral treatment option for hypophosphatasia, potentially reducing the need for enzyme replacement therapy.
- What could go wrong
- This is a very early Phase 1/2a trial with only 120 participants, focused on safety and dosing. It is too soon to know if ALE1 will be effective or safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA (HPP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit
RECRUITINGLeeds, United Kingdom
-
New Zealand Clinical Research
RECRUITINGGrafton, Auckland, 1010, New Zealand
-
Universitätsklinikum Würzburg
RECRUITINGWürzburg, 97074, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.